Picture of Acusphere logo

ACUS Acusphere Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+0.85%
3m-5.13%
6m-13.32%
1yr-14.03%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-562.14%
Return on Equityn/a
Operating Margin-1923.73%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 200931st Dec 2010
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2009 / 2010

Blurred out image of Acusphere EPS forecast chart

Profile Summary

Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).

Directors

Last Annual
December 31st, 2008
Last Interim
December 31st, 2008
Incorporated
July 12th, 1993
Public Since
October 8th, 2003
No. of Employees
118
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
4,950,677

ACUS Share Price Performance

Similar to ACUS

Picture of Acacia Diversified Holdings logo

Acacia Diversified Holdings

us flag iconPink Sheets on Nasdaq

Picture of Adorbs logo

Adorbs

us flag iconPink Sheets on Nasdaq

Picture of Agentix logo

Agentix

us flag iconPink Sheets on Nasdaq

Picture of Agrios Global Holdings logo

Agrios Global Holdings

us flag iconPink Sheets on Nasdaq

Picture of Aida Pharmaceuticals logo

Aida Pharmaceuticals

us flag iconPink Sheets on Nasdaq

FAQ